Sign In
Free Newsletter
GlaxoSmithKline wins takeover bid for Human Genome
U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people with diabetes and heart disease. The two companies said Monday that GSK will pay $3.6 […]
Report: GSK in deal talks with Human Genome
NEW YORK — GlaxoSmithKline PLC is reportedly talking this weekend with Human Genome Sciences Inc. about its $2.6 billion offer for the Rockville-based biotech company. British drug maker GlaxoSmithKline made its first bid for the biotech company in April and extended its offer of $13 per share until July 20. Human Genome Sciences has dismissed […]
Human Genome adopts ‘poison pill’ measure
ROCKVILLE — Biotech drugmaker Human Genome Sciences Inc.’s board has adopted a “poison pill” shareholder rights plan to ward off unsolicited takeover bids, and it also has rejected a buyout offer worth nearly $2.6 billion from British pharmaceutical giant GlaxoSmithKline PLC. The Rockville company said Thursday its plan lasts for a year and will dilute […]
GlaxoSmithKline in takeover bid for Human Genome
LONDON — GlaxoSmithKline PLC has made an offer to take over Rockville-based drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, said Wednesday it is offering $13 cash per share for the company. A private offer […]
Human Genome rejects GlaxoSmithKline’s $2.59B bid
The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. The question is by how much. “For the most part, we think it’s a fair offer,” said Lauren Migliore, an equity analyst with Chicago-based Morningstar. […]
Rockville-based Human Genome Sciences gets approval for new lupus drug
Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced. The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in […]
Human Genome’s lupus drug wins approval
WASHINGTON — The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical experts say could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder. Known as Benlysta, the injectable drug is designed to relieve […]
FDA scrutinizes benefit of long-awaited lupus drug
WASHINGTON — Federal health officials said Friday that the first new drug developed to treat lupus in decades relieves disease symptoms, but they questioned the significance of its benefits, which varied across difference patient groups. Human Genome Sciences is asking the Food and Drug Administration to approve Benlysta to relieve symptoms of lupus, a difficult-to-treat […]
